Related Experiment Videos
Phototherapy for cutaneous T-cell lymphoma
1Department of Dermatology, University Hospitals of Cleveland/Case Western Reserve University, and Veterans Affairs Medical Center, Cleveland, Ohio 44106, USA. edb@po.cwru.edu
Dermatologic Therapy
|December 23, 2003
Summary
Phototherapy, using various light sources like UVB and PUVA, effectively treats cutaneous T-cell lymphoma (CTCL) based on disease stage. Ongoing research explores combination therapies to enhance efficacy and minimize side effects.
Area of Science:
- Dermatology
- Photomedicine
- Oncology
Background:
- Phototherapy has a long history in treating dermatologic conditions.
- Cutaneous T-cell lymphoma (CTCL) is a primary indication for phototherapy.
- Treatment selection depends heavily on the stage of CTCL.
Purpose of the Study:
- To review the efficacy of different phototherapy modalities for CTCL.
- To discuss the role of phototherapy in various stages of CTCL.
- To explore phototherapy as an adjunct to other CTCL treatments.
Main Methods:
- Review of existing literature on phototherapy for CTCL.
- Comparison of broadband UVB, PUVA, narrowband UVB, and UVA1 efficacy.
- Analysis of phototherapy's use as monotherapy and combination therapy.
Main Results:
- Broadband UVB is effective for patch-stage CTCL.
- PUVA can clear plaques and early tumors, with long-term remissions possible but often requiring maintenance.
- Narrowband UVB and UVA1 show promise, with UVA1 inducing apoptosis; further research is needed for narrowband UVB.
- Phototherapy is effective as monotherapy for early stages and as an adjunct to treatments like interferons, retinoids, and electron beam therapy.
Conclusions:
- Phototherapy modalities vary in efficacy based on CTCL stage.
- Combination therapies are being investigated to improve CTCL treatment outcomes.
- Phototherapy remains a valuable treatment option for CTCL, with ongoing research to optimize its use.